Assessment of serum endocan levels in patients with beta-thalassemia minor.

Creative Commons License

Khanmammadov N., Zorlu M., Ozer Ö. F., Karatoprak C., Kıskaç M., Çakırca M.

Revista da Associacao Medica Brasileira (1992), vol.68, no.2, pp.147-151, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.1590/1806-9282.20210753
  • Journal Name: Revista da Associacao Medica Brasileira (1992)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.147-151
  • Keywords: Thalassemia, Anemia, Endothelial cells, Proteoglycan, ERYTHROCYTE SEDIMENTATION-RATE, ADHESION MOLECULES, HYPERTENSION
  • Bezmialem Vakıf University Affiliated: Yes


OBJECTIVE: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. METHODS: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. RESULTS: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85 +/- 88.1 pg/mL in the beta-thalassemia minor group and 236.1 +/- 162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). CONCLUSIONS: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.